JP5518489B2 - 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果 - Google Patents

頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果 Download PDF

Info

Publication number
JP5518489B2
JP5518489B2 JP2009549130A JP2009549130A JP5518489B2 JP 5518489 B2 JP5518489 B2 JP 5518489B2 JP 2009549130 A JP2009549130 A JP 2009549130A JP 2009549130 A JP2009549130 A JP 2009549130A JP 5518489 B2 JP5518489 B2 JP 5518489B2
Authority
JP
Japan
Prior art keywords
bryostatin
pkc
pharmaceutical composition
injury
head
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009549130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518091A5 (enExample
JP2010518091A (ja
Inventor
ゾハー、オファー
アルコン、ダニエル・エル．
Original Assignee
ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート filed Critical ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート
Publication of JP2010518091A publication Critical patent/JP2010518091A/ja
Publication of JP2010518091A5 publication Critical patent/JP2010518091A5/ja
Application granted granted Critical
Publication of JP5518489B2 publication Critical patent/JP5518489B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2009549130A 2007-02-09 2008-02-11 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果 Active JP5518489B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90033807P 2007-02-09 2007-02-09
US60/900,338 2007-02-09
US92466307P 2007-05-24 2007-05-24
US60/924,663 2007-05-24
PCT/US2008/001755 WO2008100449A2 (en) 2007-02-09 2008-02-11 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013261788A Division JP6199176B2 (ja) 2007-02-09 2013-12-18 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果

Publications (3)

Publication Number Publication Date
JP2010518091A JP2010518091A (ja) 2010-05-27
JP2010518091A5 JP2010518091A5 (enExample) 2011-07-28
JP5518489B2 true JP5518489B2 (ja) 2014-06-11

Family

ID=39690678

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009549130A Active JP5518489B2 (ja) 2007-02-09 2008-02-11 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果
JP2013261788A Expired - Fee Related JP6199176B2 (ja) 2007-02-09 2013-12-18 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果
JP2016016127A Pending JP2016128486A (ja) 2007-02-09 2016-01-29 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013261788A Expired - Fee Related JP6199176B2 (ja) 2007-02-09 2013-12-18 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果
JP2016016127A Pending JP2016128486A (ja) 2007-02-09 2016-01-29 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果

Country Status (8)

Country Link
US (2) US9974832B2 (enExample)
EP (4) EP2121000B1 (enExample)
JP (3) JP5518489B2 (enExample)
KR (2) KR20090119894A (enExample)
CN (1) CN101848726A (enExample)
CA (2) CA2674773A1 (enExample)
ES (1) ES2548766T3 (enExample)
WO (1) WO2008100449A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305234T3 (es) 2001-02-27 2008-11-01 Blanchette Rockefeller Neurosciences Institute Diagnostico de la enfermedad de alzheimer basado en la fosforilacion de una proteina quinosa activada por mitogeno.
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
WO2007016202A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
KR20090120480A (ko) * 2007-02-09 2009-11-24 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 허혈/뇌졸중-유도된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련된 물질의 치료학적 효과
WO2008100449A2 (en) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
WO2008143880A2 (en) * 2007-05-24 2008-11-27 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury
US20100168219A1 (en) * 2008-12-31 2010-07-01 Jonathan Steven Alexander Chronic inflammation and transplantation
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
WO2010014588A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
CA2941035A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
US20110054040A1 (en) * 2008-12-22 2011-03-03 Department Of Biotechnology Bicyclic Triterpenoid Iripallidal as a Novel Anti-Glioma and Anti-Neoplastic Therapy
US20110212474A1 (en) 2009-10-02 2011-09-01 Blanchette Rockefeller Neurosciences Institute Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells
JP6058395B2 (ja) 2009-10-02 2017-01-11 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病の診断のための繊維芽細胞成長パターン
WO2012006516A2 (en) 2010-07-08 2012-01-12 Alkon Daniel L Dag-type and indirect protein kinase c activators and anticoagulant for the treatment of stroke
KR101467605B1 (ko) * 2010-11-29 2014-12-04 충북대학교 산학협력단 신규의 다프난 디테르펜계 화합물 및 이를 유효성분으로 포함하는 피부 미백용 조성물
JP6563193B2 (ja) 2011-11-13 2019-08-21 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｄｃｐｌａのエステル、およびそれを用いた処置の方法
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
US10828276B2 (en) 2012-11-28 2020-11-10 Aphios Corporation Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
WO2014145316A1 (en) 2013-03-15 2014-09-18 Alkon Daniel L Methods for identifying neuroprotective pkc activators
WO2018034318A1 (ja) 2016-08-18 2018-02-22 国立大学法人 奈良先端科学技術大学院大学 免疫調節剤
WO2019222564A1 (en) * 2018-05-18 2019-11-21 Neurotrope Bioscience, Inc. Methods and compositions for treatment of alzheimer's disease

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
EP0115472A3 (de) 1983-01-27 1985-10-02 Ciba-Geigy Ag Pyrrolidinonderivate und Verfahren zu ihrer Herstellung
US4611066A (en) 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US5891906A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Polyacetate-derived phorboids having anti-inflammatory and other uses
US6043270A (en) 1986-06-11 2000-03-28 Procyon Pharmaceuticals, Inc. Protein kinase C modulators V
US5891870A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Protein kinase C modulators Q
US6080784A (en) 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US5955501A (en) 1986-06-11 1999-09-21 Procyon Pharmaceuticals, Inc. Protein kinase C modulators O
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
ATE97321T1 (de) 1988-01-13 1993-12-15 Univ Arizona State Immunmodulierende bryostatine.
US4833139A (en) * 1988-01-25 1989-05-23 Hoechst-Roussel Pharmaceuticals, Inc. Enhancing cholinergic activity with 5-substituted 1-[4-(1-pyrrolidinyl)-2-butynyl]-2-pyrrolidinones and related compounds
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US4994472A (en) 1989-08-02 1991-02-19 Hoechst-Roussel Pharmaceuticals Incorporated 1-(pyridinylamino)-2-pyrrolidinones as pain relievers
EP0502060A4 (en) 1989-11-13 1993-05-05 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
JP2578001B2 (ja) 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
US5072004A (en) 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5981165A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5196447A (en) 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
CA2143848C (en) 1992-10-01 2007-09-11 W. Clark Still Complex combinatorial chemical libraries encoded with tags
JPH06279311A (ja) 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤
US5580748A (en) * 1993-05-03 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tests for alzheimers disease
US5976816A (en) * 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US5393897A (en) 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5362899A (en) 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
ATE176906T1 (de) 1993-09-30 1999-03-15 Shionogi & Co Benzolactam-derivate
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5430053A (en) * 1994-04-19 1995-07-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of dictyostatin 1
US5625232A (en) * 1994-07-15 1997-04-29 Texas Instruments Incorporated Reliability of metal leads in high speed LSI semiconductors using dummy vias
EP0854874B1 (en) * 1994-11-10 2003-05-02 Pfizer Inc. Macrocyclic lactone compounds and their production process
GB9509572D0 (en) 1995-05-11 1995-07-05 Cancer Res Campaign Tech Cancer therapy
CA2253463A1 (en) 1996-05-10 1997-11-20 Georgetown University 8-hydrocarbyl substituted benzodizocine derivatives, their preparation and their use as protein kinase c (=pkc) modulators
GB9620390D0 (en) * 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9701675D0 (en) 1997-01-28 1997-03-19 Bridgeman Keith Composition for the treatment of parkinson's disease
PL339219A1 (en) 1997-09-08 2000-12-04 Univ Georgetown Substituted 2-pyrolydinones as pkc activators
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
DE19943198A1 (de) 1999-09-09 2001-03-15 Meyer Lucas Gmbh & Co Therapeutikum zur Behebung zentralnervöser Funktionsstörungen
JP2003515601A (ja) * 1999-11-30 2003-05-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ ブリオスタチンアナログ、合成方法および使用
JP2001240581A (ja) 2000-02-29 2001-09-04 Senju Pharmaceut Co Ltd アミノベンズアミド誘導体およびその用途
AU2001243635A1 (en) * 2000-03-14 2001-09-24 Brown University Research Foundation Methods and compositions for regulating memory consolidation
US20040019018A1 (en) 2000-04-28 2004-01-29 Lixin Qlao Rigid pyrrolidone modulators of pkc
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
US20030050302A1 (en) * 2000-08-31 2003-03-13 Neurologic, Inc. Treatment of conditions associated with amyloid processing using PKC activators
DK1195159T3 (da) 2000-10-09 2006-10-02 Matthias Dr Med Rath Terapeutisk kombination af ascorbat med lysin og arginin til forebyggelse eller behandling af cancer
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
AUPR215700A0 (en) 2000-12-19 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid compound having cyclopropane ring
EP1363606A1 (en) 2001-03-01 2003-11-26 Pfizer Products Inc. Use of gaba[a] inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators or vitamin e for the treatment of coginitive disorders
WO2002083877A1 (en) 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
US20040247571A1 (en) 2001-04-23 2004-12-09 Xia Meijer Neural cells expressing tyrosine hydroxylase
CA2446074C (en) 2001-05-02 2011-09-06 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
CA2401452A1 (en) 2001-09-04 2003-03-04 Uri Saragovi Combination of antioxidant substances for the treatment of alzheimer's disease
JP4568464B2 (ja) 2001-11-07 2010-10-27 雪印乳業株式会社 記憶障害予防治療剤
WO2004004641A2 (en) * 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
US6821979B2 (en) 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) * 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
US7803400B2 (en) * 2002-12-03 2010-09-28 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
NZ546226A (en) 2003-09-30 2009-03-31 Shire Llc Oxycodone conjugates for prevention of overdose or abuse
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
EP1761805B1 (en) 2004-06-30 2013-05-01 Shell Internationale Research Maatschappij B.V. Determining in-situ the relation between seismic velocity and state of stress in an underground formation
WO2007016202A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
WO2007044094A1 (en) 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
JP2009544753A (ja) * 2006-07-28 2009-12-17 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 細胞成長、シナプスリモデリング及び長期記憶の固定を刺激する方法
WO2008100449A2 (en) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
JP5987867B2 (ja) 2014-07-10 2016-09-07 コニカミノルタ株式会社 シート搬送装置および画像形成システム

Also Published As

Publication number Publication date
EP3332797A3 (en) 2018-08-01
EP2121000A2 (en) 2009-11-25
CA2674773A1 (en) 2008-08-21
US20080207742A1 (en) 2008-08-28
EP2754448A3 (en) 2014-12-24
US20190083575A1 (en) 2019-03-21
WO2008100449A2 (en) 2008-08-21
CN101848726A (zh) 2010-09-29
WO2008100449A4 (en) 2009-07-30
KR20090119894A (ko) 2009-11-20
EP2959914A1 (en) 2015-12-30
WO2008100449A3 (en) 2009-05-22
EP2754448A2 (en) 2014-07-16
KR20140049054A (ko) 2014-04-24
JP2014088406A (ja) 2014-05-15
JP2010518091A (ja) 2010-05-27
EP3332797A2 (en) 2018-06-13
ES2548766T3 (es) 2015-10-20
JP2016128486A (ja) 2016-07-14
EP2121000B1 (en) 2015-09-23
US9974832B2 (en) 2018-05-22
JP6199176B2 (ja) 2017-09-20
CA2873179A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
JP5518489B2 (ja) 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果
US10010584B2 (en) Treatment of depressive disorders
JP6017405B2 (ja) 虚血／卒中誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果
WO2008143880A2 (en) Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury
US20220184028A1 (en) Treatment of amyotrophic lateral sclerosis using pkc activators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140402

R150 Certificate of patent or registration of utility model

Ref document number: 5518489

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250